Successful allogeneic human pluripotent stem cell (hPSC)-derived therapies must overcome immunological rejection by the recipient. To build reagents to define these barriers, we genetically ablated β2M, TAP1, CIITA, CD74, MICA, and MICB to limit expression of HLA-I, HLA-II, and natural killer (NK) cell activating ligands in hPSCs. Transplantation of these cells that also expressed covalent single chain trimers of Qa1 and H2-Kb to inhibit NK cells and CD55, Crry, and CD59 to inhibit complement deposition led to persistent teratomas in wild-type mice. Transplantation of HLA-deficient hPSCs into mice genetically deficient in complement and depleted of NK cells also led to persistent teratomas. Thus, T cell, NK cell, and complement evasion are necessary to prevent immunological rejection of hPSCs and their progeny. These cells and versions expressing human orthologs of immune evasion factors can be used to define cell type-specific immune barriers and conduct preclinical testing in immunocompetent mouse models.

Original languageEnglish
Pages (from-to)299-313
Number of pages15
JournalStem Cell Reports
Issue number2
StatePublished - Feb 13 2024


  • T cells
  • Transplantation
  • complement
  • human Pluripotent Stem Cells
  • natural killer cells
  • rejection


Dive into the research topics of 'Engineering human pluripotent stem cell lines to evade xenogeneic transplantation barriers'. Together they form a unique fingerprint.

Cite this